Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Joanne S. Eglovitch

Senior Editor

Washington DC
Joanne Serpick Eglovitch is a senior editor for Pink Sheet where she writes about manufacturing quality issues. Joanne has over 20 years of experience covering the regulated pharmaceutical and medical device industries, and helped launch the “International Pharmaceutical Regulatory Monitor” and the “International Medical Device Regulatory Monitor”. Previously Joanne covered the mortgage finance industry and the mortgage capital markets, and employment and training programs. Before her forays into newsletter journalism, Joanne worked as a general assignment reporter for a twice-weekly newspaper in southern Maryland and an editorial assistant for “Insight” Magazine, published by “The Washington Times.”
Advertisement
Set Alert for Articles By Joanne S. Eglovitch

Latest From Joanne S. Eglovitch

US FDA Warning Letter Draws Indian Solvent Recycler Into Valsartan Crisis

Lantech’s solvent recovery operations expected to meet US drug GMP requirements due to risk of carcinogens in blood pressure medications.

Manufacturing Quality

Do Not Be So Quick To Blame Microbes On The Lab, The US FDA Warns Emcure

Emcure's Hinjwadi, India, plant should have investigated other more likely sources of contamination more thoroughly, the FDA says.
Manufacturing Quality

PDSA Asks Stakeholders To Join DSCSA Track-And-Trace Governing Body By September

But there’s a wrinkle: Many prospective participants cannot budget for the tiered fees until 2020.

United States Manufacturing

The FDA Aims To Strike Balance On Inspecting Physicians Who Compound Drugs

Just how much will the FDA look the other way when it comes to inspecting physician compounders?

 

Manufacturing Quality

Vasopressin Ruling May Greenlight More FDA Limits On Bulk Drug Compounding

By siding with the FDA against bulk compounding of vasopressin, is court encouraging more limits to Section 503B outsourcing facilities?

Manufacturing Quality

Is Another Heparin Crisis Looming? Congress Raises Alarm, Demands US FDA Briefing

The FDA must explain how it will prevent heparin adulteration as a virus kills pigs in China again.

United States Manufacturing
See All
Advertisement
UsernamePublicRestriction

Register